Company Announcement

IMAGION BIOSYSTEMS LIMITED

ASX: IBX

11 August 2025

Settlement of Tranche One of A$3.5M Capital Raising & Cleansing Notice

Imagion Biosystems (ASX: IBX) (**Company** or **Imagion**), a company dedicated to improving healthcare outcomes through the early detection of cancer cells utilising its proprietary MagSense® imaging technology, is pleased to announce that it has completed settlement of Tranche 1 of the $3.5 million capital raising announced 4 August 2025.

Tranche 1 of Capital Raising Completed

The Company confirms it has received $0.675m and settled Tranche 1 of its capital raising, utilising the Company's existing placement capacity under ASX Listing Rule 7.1 and 7.1A. As previously announced Tranche 1 of the placement comprised 45.0 million new ordinary shares that were issued at a price of $0.015 per new share. An appendix 2A setting out the issue of Tranche 1 shares will follow this release.

The second tranche of the placement, raising a further $2.8 million, is set to complete once shareholder approval is obtained at an Extraordinary General Meeting (EGM) scheduled for September 2025.

Participants in both tranches of the placement are to receive one free attaching listed option per new share subscribed for, subject to approval of the shareholders at the EGM. The new listed options will be issued under the same terms as the Company's existing listed options (IBXO), exercisable at $0.04 per listed option and expire on 13 December 2027.

Funds from the second tranche are expected to be received shortly after shareholder approval being granted at the EGM with new ordinary shares and new listed options expected to be allocated soon after receipt of funds.

Section 708A Cleansing Notice

The Company gives notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) that:

(a) it issued 45,000,000 fully paid ordinary shares (Shares) at an issue price of $0.015 (1.5 cents) on 11 August 2025;

(b) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;

Imagion Biosystems Limited
ASX: IBX ACN 616 305 027
Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000
http://www.imagionbiosystems.com/ | investor@imagionbio.com

(c) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act

(d) as at the date of this notice the Company has complied with:

i. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

ii. sections 674 and 674A of the Corporations Act; and

(e) as at the date of this notice, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed pursuant to section 708A(6)(e).

Authorisation & Additional Information

This announcement was authorised by the Board of Imagion Biosystems Limited.

— ENDS —

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible.

For more information, visit https://imagionbiosystems.com/investor-hub/

Media & Investor Relations:
Email: info@imagionbio.com
AU: +61 3 9692 7222

Forward-looking statements

This announcement may contain certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this announcement are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of the Company, its directors and management. This includes statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based.

These statements may assume the success of the Company's business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of the Company, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this announcement. The forward-looking statements are based on information available to the Company as at the date of this announcement. Except as required by law or regulation (including the ASX Listing Rules), none of the Company, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.